Pfizer has become the first drugmaker to agree to implement a most-favored nation (MFN) pricing agreement, matching U.S. prices to comparable developed nations. The agreement includes launching a direct-to-consumer platform, TrumpRx, offering discounts averaging over 50% on Pfizer products. This deal signals a strategic industry response to governmental pressure to lower U.S. drug prices. However, questions remain regarding coverage applicability, affecting commercial insurance and out-of-pocket payers. Industry experts anticipate other pharmaceutical companies adopting similar pricing models.